A trial to investigate how newly-discovered factors in the blood may affect the health and wellbeing of people with kidney disease
- Conditions
- Chronic kidney diseaseUrological and Genital Diseases
- Registration Number
- ISRCTN73106458
- Lead Sponsor
- niversity Hospitals of Leicester NHS Trust
- Brief Summary
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35090033/ (added 18/09/2023) Results article in https://pubmed.ncbi.nlm.nih.gov/35452395/ (added 18/09/2023) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35029054/ (added 18/09/2023)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 38
Kidney disease patient:
1. Established CKD according to these guidelines : http://www.gpnotebook.co.uk/simplepage.cfm?ID=x20140903131721906919
or identified with the IMPAKT tool : http://www.impakt.org.uk/HOME-459.html
2. Willing and able to give informed consent and comply with the study protocol
3. Male or female
4. Aged 18 years or above
Healthy control:
1. Willing and able to give informed consent and comply with the study protocol.
2. Male or female
3. Aged 18 years or above.
Both kidney disease patients and healthy controls:
1. Age <18 years
2. Any other significant disease or disorder which, in the opinion of the patient’s own clinician, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study.
3. Inability to give informed consent or comply with the protocol for any reason.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Circulating markers of oxidative stress, pro/anti-inflammatory status, immune parameters and relevant genotyping are measured from a blood sample at entry and up to 5 further timepoints in a 36 month period
- Secondary Outcome Measures
Name Time Method